Alzheimer’s drug developers accuse clinical trial sites of faking data

Science | AAAS· June 20, 2026

Pharmaceutical developers working on Alzheimer’s disease treatments have leveled accusations of data falsification against certain clinical trial sites. These allegations point to potential misconduct in how patient data was recorded or reported during the testing of experimental therapies. For the clinical research and CRO industry, these claims highlight systemic risks regarding data integrity and the vital importance of stringent site monitoring protocols in high-profile therapeutic areas.

Read the full story at Science | AAAS

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Science | AAAS.

More in Clinical Research & CRO

Research Sites Push for Sponsor and CRO Support as Administrative Costs Mount

A new analysis from researchers at the Morehouse School of Medicine, Sanofi, and ICON highlights the growing financial strain on clinical trial sites caused by increasing administrative complexity. As drug studies become more intricate, sites are struggling with the costs of regulatory compliance, vendor oversight, and technology integration, which often outpace traditional budgeting models. Addressing these burdens is critical for the Clinical Research & CRO sector to ensure site sustainability and prevent operational failures that could disrupt drug development pipelines.

June 21, 2026

RyghtAI launches clinical site search engine to aid drug developers, CROs with trial design

RyghtAI has introduced RyghtSites.com, a free search engine designed to streamline the clinical site selection process for drug developers and contract research organizations (CROs). The platform leverages a proprietary network of AI Site Twins to provide data-driven insights into over 100,000 research sites globally. By addressing traditional delays in site identification, the tool aims to mitigate the common industry challenge where 80% of clinical trials fail to meet enrollment deadlines.

June 20, 2026

Dr. Vince Clinical Research Expands CRO Capabilities as William Lavery, MD, PhD, Earns Board Certification in Obesity Medicine

Dr. Vince Clinical Research (DVCR) has announced an expansion of its contract research organization (CRO) capabilities following a key certification for its medical staff. William Lavery, MD, PhD, has earned board certification in obesity medicine, positioning the firm to better support clinical trials in the metabolic and weight management space. This development reflects the growing demand for specialized expertise in obesity-related research within the clinical development sector.

June 20, 2026

Canadian CRO Somru BioScience acquires Novus Clinical Research to expand global network

Canadian contract research organization Somru BioScience Inc. has announced the 100% acquisition of Bangladesh-based Novus Clinical Research Services Limited. This strategic move aims to create an integrated clinical research platform bridging North America and South Asia to accelerate the development of vaccines, biosimilars, and other therapies. The acquisition represents a significant expansion of Somru’s global footprint and a boost to the clinical research infrastructure in Bangladesh through technology transfer and laboratory modernization.

June 20, 2026